Psilocybin by Filament Health for Treatment Resistant Depression: Likelihood of Approval

Psilocybin is under clinical development by Filament Health and currently in Phase I for Treatment Resistant Depression.

Valproic acid shows promise in reducing COVID-19 severity and hospitalization

Researchers found that valproic acid (VPA), especially when combined with DHA, significantly reduces SARS-CoV-2 infection rates and severity, potentially activating antiviral mechanisms. Epidemiologic data support

August 6, 2024

‘Personalized’ Approach to RT for Bladder Cancer Promising but Challenging

A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and survival comparable to historical results with

October 14, 2024

Protesters slam health insurance lobby for Medicare Advantage coverage restrictions

WASHINGTON — Hundreds of activists rallied today outside of the headquarters of the country’s largest health insurance lobbying group to protest against restrictions to coverage

June 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.